Loading...
 
Back to the list
Mediterr J Rheumatol 2020;31(2):235-8
Article Links
Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin
Aliki I. Venetsanopoulou, Theodora E. Markatseli, Michail P. Migkos, Athanasios Georgiadis, Foivos S. Kanellos, Alexandros A. Drosos, Paraskevi V. Voulgari
Authors Information

Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Keywords: psoriatic arthritis, interleukin 17, interleukin 23, sclerostin
References
  1. Ogdie A, Weiss P. The Epidemiology Psoriatic Arthritis. Rheum Dis Clin North Am 2015 Nov;41(4): 545-68.
  2. Alamanos Y, Papadopoulos NG, Voulgari PV, Siozos C, Psychos DN, Tympanidou M, et al. Epidemiology of psoriatic arthritis in northwest Greece, 1982-2001. J Rheumatol 2003;30:2641-4.
  3. Scotti L, Franchi M, Marchesoni A, Corrao G. Revalence and incidence of psoriatic arthritis: A systematic review and meta-analysis.Semin Arthritis Rheum 2018 Aug;48(1):28-34.
  4. Gisondi P, Girolomini G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian Patients hospitalized for psoriasis. Eur J Dermatol 2005;15:279-83.
  5. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical futures, course and outcome. Ann Rheum Dis 2005;64 (suppl II):ii14-ii17.
  6. Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. WienKlinWochenschr 2016 Nov;128(21-22):791-5.
  7. Gladman DD. Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. Rheum Dis Clin North Am 2015 Nov;41(4):569-79
  8. Pietrzak D, Pietrzak A, Krasowska D, Borzęcki A, Franciszkiewicz-Pietrzak K, Polkowska-Pruszyńska B, et al. Digestive system in psoriasis: an update. Arch Dermatol Res 2017; 309(9):679-93.
  9. Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010 May-Jun;28(3):304-10. Epub 2010 Jun 23.
  10. Punzi L, Podswiadek M, Oliviero F, Lonigro A, Modesti V, et al. Laboratory findings in psoriatic arthritis. Reumatismo 2007;59 Suppl 1:52-5.
  11. Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat Commun 2018;9:4178.
  12. Yan D, Ahn R, Leslie S, Liao W. Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis. Dermatol Ther (Heidelb) 2018 Dec;8(4):593-604.
  13. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 2018 Dec;55(3):379-90.
  14. Yoo IS, Lee JH, Song ST, Kim JH, Lee HJ, et al. T-helper 17 cells: the driving force of psoriasis and psoriatic arthritis. Int J Rheum Dis 2012;15:531-7.
  15. Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015;11:415-29.
  16. Liang SC, Tan X, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006 Oct 2;203(10):2271–9.
  17. El-Zayadi AA, Jones EA, Churchman SM, Baboolal TG, Cuthbert RJ, El-Jawhari JJ, et al. Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology (Oxford) 2017 Mar 1;56(3):488-93.
  18. Rahimi H, Ritchlin CT. Altered bone biology in psoriatic arthritis. Curr Rheumatol Rep. 2012;14:349-57.
  19. Xie W, Zhou L, Li S, Hui T, Chen D. Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann NY Acad Sci 2016;1364:25-31.
  20. Fassio A, Idolazzi L, Viapiana O, Benini C, Vantaggiato E, et al. In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls. Clin Rheumatol 2017;36:2377-2381.
  21. Fassio A, Gatti D, Rossini M, Idolazzi L, Giollo A, Adami G, et al. Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clinical and Experimental Rheumatology 2019;37:133-6.
  22.  Paik J, Deeks ED. Tofacitinib: A Review in Psoriatic Arthritis. Drugs 2019 Apr;79(6):655-63.
  23. Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskelet Dis 2017 Feb;9(2):45-53.
  24. Abdulrahim H, Sharlala H, Adebajo AO. An evaluation of tofacitinib for the treatment of psoriatic arthritis. Expert Opin Pharmacother 2019 Nov;20(16):1953-60.
  25. Silvagni E, Bortoluzzi A, Ciancio G, Govoni M. Biological and synthetic target DMARDs in psoriatic arthritis. Pharmacol Res 2019 Nov;149:104473.